Download Image
    
Share
  
Post
Goflikicept for COVID-19
1 study with 247 patients
Hospital Icon Control
Hospital Icon Goflikicept Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Goflikicept studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -135% Mortality -135% RCTs -135% Late -135% Favorsgoflikicept Favorscontrol
Jan 24
2022
 Samsonov et al., NCT04380519 An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)
135% higher mortality (p=0.07) and no change in improvement (p=1). RCT 248 hospitalized patients showing higher mortality (p=0.07) with goflikicept (RPH-104).